A
Aníbal Ferreira
Researcher at Nova Southeastern University
Publications - 64
Citations - 2589
Aníbal Ferreira is an academic researcher from Nova Southeastern University. The author has contributed to research in topics: Bone remodeling & Renal osteodystrophy. The author has an hindex of 22, co-authored 64 publications receiving 2285 citations. Previous affiliations of Aníbal Ferreira include Necker-Enfants Malades Hospital & Universidade Nova de Lisboa.
Papers
More filters
Journal ArticleDOI
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
Patrick C. D'Haese,Goce Spasovski,A. Sikole,Alastair J. Hutchison,Tony Freemont,Sylvie Dusilova Sulkova,Charles R. Swanepoel,Svetlana Pejanovic,Llubica Djukanovic,Alessandro Balducci,Giorgio Coen,Waldysaw Sulowicz,Aníbal Ferreira,Armando Torres,Slobodan Curic,Milan Popovic,Nada Dimkovic,Marc E. De Broe +17 more
TL;DR: LC is a poorly absorbed, well-tolerated, and efficient phosphate binder in dialysis patients, who show almost no evolution toward low bone turnover over one year (unlike CC-treated patients), nor do they experience any aluminum-like effects on bone.
Journal ArticleDOI
Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients.
TL;DR: Plasma bAP level equal or higher than 20 ng/mL, either alone or combined with plasma iPTH of 200 pg/ mL, had the highest sensitivity, specificity, and predictability values for the diagnosis of high-turnover bone disease, and formally excluded patients with normal or LTBD.
Journal ArticleDOI
Cholecalciferol Supplementation in Hemodialysis Patients: Effects on Mineral Metabolism, Inflammation, and Cardiac Dimension Parameters
Patrícia Matias,Cristina Jorge,Carina Ferreira,Marília Borges,Inês Aires,Tiago Amaral,Célia Gil,José Cortez,Aníbal Ferreira +8 more
TL;DR: Oral cholecalciferol supplementation in HD patients seems to be an easy and cost-effective therapeutic measure that allows reduction of vitamin D deficiency, better control of mineral metabolism with less use of active vitamin D, attenuation of inflammation, reduced dosing of erythropoiesis-stimulating agents, and possibly improvement of cardiac dysfunction.
Journal ArticleDOI
Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis
Stuart M. Sprague,Ezequiel Bellorin-Font,Vanda Jorgetti,Aluizio B. Carvalho,Hartmut H. Malluche,Aníbal Ferreira,Patrick C. D'Haese,Tilman B. Drüeke,Hongyan Du,Thomas Manley,Eudocia Rojas,Sharon M. Moe +11 more
TL;DR: In this paper, the parathyroid hormone (PTH) concentration was used to discriminate low from nonlow and high from nonhigh BFR/BS, with an area under the receiver operating characteristic curve > 0.70 but not more than 323.0pg/mL.
Journal ArticleDOI
Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialysis Patients
Aníbal Ferreira,João M. Frazão,Marie Claude Monier-Faugere,Célia Gil,José Galvao,Carlos Augusto Fernandes de Oliveira,Jorge Baldaia,Ilídio Rodrigues,Carla Santos,Sílvia Ribeiro,Regula Mueller Hoenger,Ajay Duggal,Hartmut H. Malluche +12 more
TL;DR: Sevelamer resulted in no statistically significant changes in bone turnover or mineralization compared with calcium carbonate, but bone formation increased and trabecular architecture improved with sevelamer.